IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Janneke E. Jaspers(Memorial Sloan Kettering Cancer Center), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center)
Cited by 165
Related Papers
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
|Blood|2016|398
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
|Scientific Reports|2017|397
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
|Blood|2019|277
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
|Molecular Therapy Oncology|2024|9